Market News

Forest Laboratories (FRX)

Oppenheimer initiated coverage for Forest Laboratories, Inc. with a recommendation of Outperform.

Dec 17 · 8:31:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

EXACT Sciences Corporation (EXAS)

Robert W. Baird initiated coverage for EXACT Sciences Corporation with a recommendation of Outperform.

Dec 17 · 8:30:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Biovail Corporation (BVF)

Thomas Weisel initiated coverage for Biovail Corporation with a recommendation of Overweight.

Dec 17 · 8:28:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Auxilium Pharmaceuticals Inc. (AUXL)

Jefferies & Co initiated coverage for Auxilium Pharmaceuticals Inc. with a recommendation of Buy.

Dec 17 · 8:27:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Arena Pharmaceuticals Inc. (ARNA)

Jefferies & Co initiated coverage for Arena Pharmaceuticals Inc. with a recommendation of Hold.

Dec 17 · 8:26:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Amylin Pharmaceuticals Inc. (AMLN)

Jefferies & Co initiated coverage for Amylin Pharmaceuticals Inc. with a recommendation of Buy.

Dec 17 · 8:25:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

AstraZeneca and the University of Virginia in Charlottesville Tuesday announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).
http://www.prnewswire.com/news-releases/astrazeneca-and-the-university-of-virginia-sign-strategic-research-collaboration-to-develop-novel-treatments-for-cardiovascular-disease-79304982.html

Dec 15 · 10:42:00 AM
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Gilead Sciences (GILD)

U.S. Food and Drug Administration staff cited concerns on Tuesday with the design and analysis of clinical studies intended to support the effectiveness of Gilead Sciences's experimental cystic fibrosis drug.
"There are concerns that assumptions used in the analysis could have been determined retrospectively," the staff said in their 48-page briefing document.

Dec 8 · 3:17:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Previous · Next